DuPont and Inbiose infant formula HMO gains EU approval
The ingredient 2’-Fucosyllactose (2’-FL) is to be marketed by DuPont under the brand name CARE4U, having already been approved for use in dietary supplements.
DuPont have earmarked the HMO as a core ingredient in potential applications for the future that are related to digestion and immune health.
“The substantial equivalence dossier for 2’-FL received EU Novel Food approval in December 2017,” said Paul Tenning, DuPont’s regulatory affairs manager, EMEA.
“We are excited to be able to bring this important new ingredient for infants and children into the European market.”
2016 agreement
News of regulatory approval for 2’FL means the firms’ joint development and licensing agreement to produce and commercialise 2’-FL, agreed back in 2016 are on track.
This agreement, which also looks to develop other fucosylated HMOs, combines Inbiose’s carbohydrate production platform with DuPont’s industrial-scale fermentation facilities.
“After many years of research and investment, we are delighted to see the first of our range of human milk oligosaccharides becoming commercially available, thus addressing a major gap in the nutritional composition of infant formula,” said Professor Wim Soetaert, Inbiose’s executive chairman.
“Thanks to our collaboration with DuPont, our first HMO is now commercialised, with many others to come.”
Cost-effective HMO production
HMOs are a group of unique oligosaccharides found in mother’s milk, wi...
Source: Nursing Comments - Category: Nursing Authors: M1gu3l Tags: Nutrition Source Type: blogs
More News: Allergy | Allergy & Immunology | Belgium Health | Biotechnology | Brain | Carbohydrates | Chemistry | Child Development | Children | Complementary Medicine | Diarrhoea | Diets | Learning | Milk | Neurology | Nurses | Nursing | Nutrition | Universities & Medical Training